GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Curocell Inc (XKRX:372320) » Definitions » Net Income From Continuing Operations

Curocell (XKRX:372320) Net Income From Continuing Operations : ₩-29,574.85 Mil (TTM As of Jun. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Curocell Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Curocell's net income from continuing operations for the six months ended in Jun. 2023 was ₩-12,610.70 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Jun. 2023 was ₩-29,574.85 Mil.

Curocell Net Income From Continuing Operations Historical Data

The historical data trend for Curocell's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Curocell Net Income From Continuing Operations Chart

Curocell Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Net Income From Continuing Operations
-15,038.33 -7,699.23 -53,575.67 -38,885.13 -29,574.85

Curocell Semi-Annual Data
Jun22 Dec22 Jun23 Dec23
Net Income From Continuing Operations -26,212.14 -12,672.99 -12,610.70 -16,964.15

Curocell Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₩-29,574.85 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Curocell (XKRX:372320) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Curocell Inc (XKRX:372320) » Definitions » Net Income From Continuing Operations
Comparable Companies
Traded in Other Exchanges
N/A
Address
11, Gukjegwahak 16-ro, Yuseong-gu, Daejeon, KOR, 34002
Website
https://www.curocellbtx.com
Curocell Inc is engaged in medical and pharmaceutical research and development. The company is into development of CAR-T treatments that enhance the natural function of immune cells to eliminate cancer cells through genetic manipulation of human immune cells.

Curocell (XKRX:372320) Headlines

No Headlines